Company news

Oragenics Inc. news in 2026

Oragenics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Investor Presentation - May 2026

May 19, 2026

Oragenics provides investor update

May 18, 2026

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

May 7, 2026

Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.

May 5, 2026

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

April 20, 2026

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

April 13, 2026

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

March 25, 2026

Oragenics files annual report on Form 10-K

March 17, 2026

Oragenics initiates Phase IIa clinical trial site activation

March 12, 2026

Oragenics explores expansion of CNS platform pursuing acquistion of assets in brain health, recovery, and neuroprotection

March 11, 2026

Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

March 10, 2026

Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

February 9, 2026

Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

February 3, 2026

Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

February 2, 2026

Investor Presentation - January 2026

January 26, 2026

Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico

January 14, 2026

Decks in 2026